Efficacy of Intravenous Immunoglobulin Combined with Prednisolone Following Resistance to Initial Intravenous Immunoglobulin Treatment of Acute Kawasaki Disease - 23/07/13
, Tomio Kobayashi, MD 3, Akihiro Morikawa, MD 1, 4, Kentaro Ikeda, MD 1, Mitsuru Seki, MD 3, Shinya Shimoyama, MD 3, Yoichiro Ishii, MD 3, Takahiro Suzuki, MD 5, Kimiko Nakajima, MD 3, Naoko Sakamoto, PhD 6, Hirokazu Arakawa, MD 1Abstract |
Objectives |
To determine the most effective first-line rescue therapy for intravenous immunoglobulin (IVIG) nonresponders, using IVIG, prednisolone, or both, to prevent coronary artery abnormalities (CAAs).
Study design |
We retrospectively reviewed the clinical records of 359 consecutive patients with Kawasaki disease who failed to respond to initial IVIG.
Results |
CAAs up to 1 month after treatment were less common in the IVIG+prednisolone group (15.9%) than in the IVIG group (28.7%, P = .005) and the prednisolone group (30.6%, P = .01). The IVIG+prednisolone group had significantly lower risks of failing to respond to first-line rescue therapy (aOR 0.16, 95% CI 0.09-0.31), CAAs up to 1 month (aOR 0.46, 95% CI 0.27-0.90), and CAAs at 1 month (aOR 0.40, 95% CI 0.18-0.91) than the IVIG group. In the prednisolone and IVIG+prednisolone groups, risk score, day of illness at first-line rescue therapy, prednisolone monotherapy, and resistance to first-line rescue therapy were independent risk factors for CAA. Sex and resistance to first-line rescue therapy were independent risk factors in the IVIG group.
Conclusions |
IVIG+prednisolone may be superior to IVIG or prednisolone as first-line rescue therapy in the treatment of IVIG nonresponders. To establish the efficacy of rescue therapy with IVIG+prednisolone following nonresponse to initial IVIG, a prospective randomized trial is warranted.
Le texte complet de cet article est disponible en PDF.Keyword : CAA, CRP, IL, IVIG, KD, mPSL
Plan
| Supported by Ministry of Health, Labor, and Welfare Sciences Grant of Comprehensive Research on Practical Application of Medical Technology (Randomized Controlled Trial to Assess Immunoglobulin plus Steroid Efficacy for Kawasaki Disease; H20-Rinsho-Shiken-Ippan-08), and the Morinaga Foundation for Health and Nutrition. T.K. received a scholarship fund (Banyu Fellowship Program 2012). The authors declare no conflicts of interest. |
Vol 163 - N° 2
P. 521 - août 2013 Retour au numéro
Article précédent
- Dental Hospital Admissions in the Children of Mothers with an Alcohol-Related Diagnosis: A Population-Based, Data-Linkage Study
- Colleen M. O'Leary, Linda M. Slack-Smith
- Dedicated Retinal Examination in Children Evaluated for Physical Abuse without Radiographically Identified Traumatic Brain Injury
- Mary V. Greiner, Rachel P. Berger, Jonathan D. Thackeray, Daniel M. Lindberg, Examining Siblings to Recognize Abuse (ExSTRA) Investigators ?
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?